Phase II Study of D-0120 and Allopurinol in Gout by InventisBio
InventisBio is conducting Phase II trial to evaluate the efficacy and safety of D-0120 in combination with Allopurinol for treating gout.
Phase II
Rheumatology / Gout
Status
Active
Sponsor
Gout
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The Phase II trial of D-0120 in combination with Allopurinol represents a significant development in the gout therapeutic landscape. If successful, it could provide a new treatment option and alter competitive dynamics within the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any announcements regarding efficacy and safety outcomes.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.